A pooled analysis of three clinical trials tested a new treatment combination, xanomeline/trospium, for schizophrenia. Over about 700 participants, the studies found that the treatment helped reduce both positive and negative symptoms compared with placebo. More patients on xanomeline/trospium showed meaningful improvements in their condition, and benefits were seen across different groups (by age, sex, race, and illness severity).
The most common side effects were mild to moderate stomach-related issues. Since the trials lasted only 5 weeks and didn’t compare this treatment directly to existing antipsychotics, longer studies are needed to confirm lasting benefits and safety.
Early results suggest xanomeline/trospium could be a promising treatment option for schizophrenia, but more research is required.
To read the full article, click here.
Contributor: Bristol Myers Squibb
